Amplia Therapeutics Limited (ASX:ATX)
Australia · Delayed Price · Currency is AUD | Market Cap | 64.13M |
| Revenue (ttm) | 5.01M |
| Net Income (ttm) | -7.93M |
| Shares Out | 513.07M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,803 |
| Average Volume | 502,658 |
| Open | 0.1250 |
| Previous Close | 0.1300 |
| Day's Range | 0.1250 - 0.1250 |
| 52-Week Range | 0.0490 - 0.4250 |
| Beta | 0.86 |
| RSI | 46.93 |
| Earnings Date | Nov 17, 2025 |
About Amplia Therapeutics
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed... [Read more]
Financial Performance
In 2024, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2023.
Financial StatementsNews
Bell Potter kicks off equity raisings for Amplia, Elsight
The shares of Amplia Therapeutics and Elsight Limited were placed in a trading halt on Monday morning.